Vicero Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vicero Bio is a private, preclinical-stage biotech developing next-generation cancer immunotherapies using its VINCOBODY platform. The platform leverages VHH (nanobody) fragments to create multi-specific biologics and antibody-drug conjugates (ADCs) designed for superior tumor penetration, reduced toxicity, and subcutaneous administration. Its lead candidate, VCR-036, is a bispecific targeting PD-1 and CTLA-4 for colorectal cancer, aiming to deliver combination efficacy without the typical severe side effects. The company is led by industry veterans with extensive experience in bringing blockbuster oncology drugs to market.

Oncology

Technology Platform

Proprietary VINCOBODY platform for engineering multi-specific and multi-payload therapeutics based on compact, modular VHH (nanobody) antibody fragments. Designed for deep tumor penetration, reduced Fc-mediated toxicity, and subcutaneous administration.

Opportunities

The primary opportunity is to capture significant market share in the large immuno-oncology space by offering safer, more effective combination therapies that can be administered subcutaneously.

Success in colorectal cancer, particularly in the microsatellite stable population, could address a major unmet need and serve as a proof-of-concept for expanding into other solid tumors.

Risk Factors

Key risks include the preclinical-to-clinical translational risk of the novel VINCOBODY format, intense competition in the bispecific antibody and ADC landscapes, and the financial and operational risks associated with being a private, early-stage biotech company dependent on fundraising.

Competitive Landscape

Vicero operates in the highly competitive fields of bispecific antibodies and next-generation ADCs, competing against large pharma (e.g., Roche, Amgen) and numerous biotechs. Its differentiation hinges on the unique safety profile and delivery advantages of its Fc-less, VHH-based platform compared to larger, IgG-based bispecifics.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →